amlodipine has been researched along with Complications of Diabetes Mellitus in 33 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This multicentre, double-blind, trial in subjects with severe hypertension compared the efficacy and tolerability of two parallel drug regimens: A/B (amlodipine/benazepril: 5/20 or 10/40 mg daily, if necessary) with A (amlodipine: 5 or 10 mg daily, if necessary)." | 9.14 | Comparative efficacy and safety of amlodipine/benazepril combination therapy and amlodipine monotherapy in severe hypertension. ( Hall, D; Hilkert, RJ; Izzo, JL; Purkayastha, D, 2010) |
| " The metabolic and renal effects of long-term (8 months) therapy with amlodipine, 5 to 10 mg daily, were studied in 15 hypertensive patients with uncomplicated diabetes mellitus as compared with 15 patients with essential hypertension." | 9.07 | Calcium antagonists for treatment of diabetes-associated hypertension. Metabolic and renal effects of amlodipine. ( Beretta-Piccoli, C; Heinen, G; Pingitore, R; Riesen, W; Zanetti-Elshater, F, 1994) |
| "High blood pressure is about twice as common in persons with diabetes mellitus as in those without." | 6.69 | Comorbidity of hypertension and diabetes: the fosinopril versus amlodipine cardiovascular events trial (FACET) ( Sowers, JR, 1998) |
| "The prevalence of hypertension is high in patients with diabetes mellitus (DM), chronic kidney disease (CKD) and chronic cardiovascular disease (CVD), as well as in black and elderly subjects." | 6.49 | Effectiveness of the fixed-dose combination of olmesartan/amlodipine/hydrochlorothiazide for the treatment of hypertension in patients stratified by age, race and diabetes, CKD and chronic CVD. ( Chrysant, SG, 2013) |
| " Tolerability was assessed by treatment-emergent adverse events." | 5.35 | Evaluation of safety and efficacy of telmisartan-amlodipine combination in treating hypertension. ( Faruqui, AA, 2008) |
| "A total of 263 type 2 diabetes with hypertension refractory to standard dose of ARB were randomized to increased ARB regimen (n=132) or amlodipine combination regimen (n=131)." | 5.16 | Management of home blood pressure by amlodipine combined with angiotensin II receptor blocker in type 2 diabetes. ( Choi, JB; Daida, H; Hayashi, D; Ikeda, S; Imai, Y; Kawamori, R; Kishimoto, J; Kitagawa, A; Miyauchi, K; Murayama, F; Ono, Y; Suwa, S; Tanaka, Y; Watada, H; Yamazaki, T, 2012) |
| "This multicentre, double-blind, trial in subjects with severe hypertension compared the efficacy and tolerability of two parallel drug regimens: A/B (amlodipine/benazepril: 5/20 or 10/40 mg daily, if necessary) with A (amlodipine: 5 or 10 mg daily, if necessary)." | 5.14 | Comparative efficacy and safety of amlodipine/benazepril combination therapy and amlodipine monotherapy in severe hypertension. ( Hall, D; Hilkert, RJ; Izzo, JL; Purkayastha, D, 2010) |
| "The ACCOMPLISH (Avoiding Cardiovascular Events Through COMbination Therapy in Patients Living With Systolic Hypertension) trial compared the outcomes effects of a renin-angiotensin system blocker, benazepril, combined with amlodipine (B+A) or hydrochlorothiazide (B+H)." | 5.14 | Cardiovascular events during differing hypertension therapies in patients with diabetes. ( Bakris, GL; Dahlöf, B; Devereux, RB; Hester, A; Hua, TA; Jamerson, K; Kelly, RY; Kjeldsen, SE; Pitt, B; Velazquez, EJ; Weber, MA; Weir, M, 2010) |
| " The metabolic and renal effects of long-term (8 months) therapy with amlodipine, 5 to 10 mg daily, were studied in 15 hypertensive patients with uncomplicated diabetes mellitus as compared with 15 patients with essential hypertension." | 5.07 | Calcium antagonists for treatment of diabetes-associated hypertension. Metabolic and renal effects of amlodipine. ( Beretta-Piccoli, C; Heinen, G; Pingitore, R; Riesen, W; Zanetti-Elshater, F, 1994) |
| " This article considers the evidence supporting telmisartan/amlodipine combination therapy for the treatment of hypertension in patients with metabolic risk factors." | 4.89 | Telmisartan plus amlodipine single-pill combination for the management of hypertensive patients with a metabolic risk profile (added-risk patients). ( Ley, L; Schumacher, H, 2013) |
| " Parallel-group, randomized, controlled trials that included at least 10 adults with baseline hypertension (SBP>or=140 mm Hg, DBP>or=90 mm Hg, or both), included at least 1 arm randomized to initial treatment with amlodipine monotherapy, had a minimum treatment duration of 8 weeks, and reported baseline and end-point blood pressure were included." | 4.82 | Effect of amlodipine on systolic blood pressure. ( Connelly, JE; Estok, RP; Fahrbach, KR; Frame, D; Levine, CB; Ludensky, V; Stone, LR, 2003) |
| " We aimed to investigate whether baseline predictors of cardiac morbidity, the major constituent of the primary endpoint in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial, were different in patients with diabetes and new-onset diabetes compared to patients without diabetes." | 2.82 | Predictors of cardiac morbidity in diabetic, new-onset diabetic and non-diabetic high-risk hypertensive patients: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial. ( Aksnes, TA; Holzhauer, B; Hua, TA; Julius, S; Kjeldsen, SE; Rostrup, M, 2016) |
| "High blood pressure is about twice as common in persons with diabetes mellitus as in those without." | 2.69 | Comorbidity of hypertension and diabetes: the fosinopril versus amlodipine cardiovascular events trial (FACET) ( Sowers, JR, 1998) |
| "Amlodipine is a classical drug with varied properties extending from control of blood pressure to as an antianginal and anti atherosclerotic agent." | 2.58 | Amlodipine in the Era of New Generation Calcium Channel Blockers. ( Kashyap, R; Langote, A; Tiwaskar, M; Toppo, A, 2018) |
| "The prevalence of hypertension is high in patients with diabetes mellitus (DM), chronic kidney disease (CKD) and chronic cardiovascular disease (CVD), as well as in black and elderly subjects." | 2.49 | Effectiveness of the fixed-dose combination of olmesartan/amlodipine/hydrochlorothiazide for the treatment of hypertension in patients stratified by age, race and diabetes, CKD and chronic CVD. ( Chrysant, SG, 2013) |
| "Amlodipine therapy was also associated with significant slowing in carotid atherosclerosis, an important surrogate marker for CAD, independent of blood pressure changes." | 2.41 | Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. ( Mason, RP, 2002) |
| "amlodipine was associated with lower BPV than other CCBs for both hypertensive patients and hypertensive patients with comorbidity." | 1.48 | Comparison of amlodipine versus other calcium channel blockers on blood pressure variability in hypertensive patients in China: a retrospective propensity score-matched analysis. ( Dong, P; Li, L; Lin, Y; Liu, D; Xie, X; Yang, J; Zhang, L, 2018) |
| "The Irbesartan Diabetic Nephropathy Trial (IDNT) demonstrated that irbesartan significantly slowed established Type 2 diabetic nephropathy progression." | 1.38 | Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial. ( Bain, SC; Bilous, RW; Evans, M; Hogan, S, 2012) |
| " Tolerability was assessed by treatment-emergent adverse events." | 1.35 | Evaluation of safety and efficacy of telmisartan-amlodipine combination in treating hypertension. ( Faruqui, AA, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (15.15) | 18.2507 |
| 2000's | 12 (36.36) | 29.6817 |
| 2010's | 16 (48.48) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sethi, BK | 1 |
| Baruah, MP | 1 |
| Kumar, AS | 1 |
| Zhang, L | 1 |
| Yang, J | 1 |
| Li, L | 1 |
| Liu, D | 1 |
| Xie, X | 1 |
| Dong, P | 1 |
| Lin, Y | 1 |
| Tiwaskar, M | 1 |
| Langote, A | 1 |
| Kashyap, R | 1 |
| Toppo, A | 1 |
| Agarwal, R | 1 |
| Weir, MR | 1 |
| Eckert, S | 1 |
| Freytag, SB | 1 |
| Müller, A | 1 |
| Klebs, SH | 1 |
| Chrysant, SG | 2 |
| Aksnes, TA | 1 |
| Kjeldsen, SE | 2 |
| Rostrup, M | 1 |
| Holzhauer, B | 1 |
| Hua, TA | 2 |
| Julius, S | 1 |
| Faruqui, AA | 1 |
| Izzo, JL | 2 |
| Purkayastha, D | 1 |
| Hall, D | 1 |
| Hilkert, RJ | 1 |
| Matsushita, K | 1 |
| Muramatsu, T | 1 |
| Kondo, T | 1 |
| Maeda, K | 1 |
| Shintani, S | 1 |
| Murohara, T | 1 |
| Weber, MA | 1 |
| Bakris, GL | 1 |
| Jamerson, K | 1 |
| Weir, M | 1 |
| Devereux, RB | 1 |
| Velazquez, EJ | 1 |
| Dahlöf, B | 1 |
| Kelly, RY | 1 |
| Hester, A | 1 |
| Pitt, B | 1 |
| Kobayashi, N | 1 |
| Ishimitsu, T | 1 |
| Evans, M | 1 |
| Bain, SC | 1 |
| Hogan, S | 1 |
| Bilous, RW | 1 |
| Miyauchi, K | 1 |
| Yamazaki, T | 1 |
| Watada, H | 1 |
| Tanaka, Y | 1 |
| Kawamori, R | 1 |
| Imai, Y | 1 |
| Ikeda, S | 1 |
| Kitagawa, A | 1 |
| Ono, Y | 1 |
| Murayama, F | 1 |
| Choi, JB | 1 |
| Suwa, S | 1 |
| Hayashi, D | 1 |
| Kishimoto, J | 1 |
| Daida, H | 1 |
| Kim, JH | 1 |
| Zamorano, J | 1 |
| Erdine, S | 1 |
| Pavia, A | 1 |
| Al-Khadra, A | 1 |
| Sutradhar, S | 1 |
| Yunis, C | 1 |
| Kereiakes, DJ | 1 |
| Littlejohn, T | 1 |
| Melino, M | 1 |
| Lee, J | 1 |
| Fernandez, V | 1 |
| Heyrman, R | 1 |
| Ley, L | 1 |
| Schumacher, H | 1 |
| Mason, RP | 1 |
| Levine, CB | 1 |
| Fahrbach, KR | 1 |
| Frame, D | 1 |
| Connelly, JE | 1 |
| Estok, RP | 1 |
| Stone, LR | 1 |
| Ludensky, V | 1 |
| Ito, A | 1 |
| Fukumoto, Y | 1 |
| Shimokawa, H | 1 |
| Coleman, JJ | 1 |
| Kendall, MJ | 1 |
| Tobe, S | 1 |
| Kawecka-Jaszcz, K | 1 |
| Zannad, F | 1 |
| Vetrovec, G | 1 |
| Patni, R | 1 |
| Shi, H | 1 |
| Io, K | 1 |
| Minatoguchi, S | 1 |
| Nishigaki, K | 1 |
| Ojio, S | 1 |
| Tanaka, T | 1 |
| Segawa, T | 1 |
| Matsuo, H | 1 |
| Watanabe, S | 1 |
| Hattori, A | 1 |
| Ueno, K | 1 |
| Ono, H | 1 |
| Hiei, K | 1 |
| Sato, H | 1 |
| Morita, N | 1 |
| Noda, T | 1 |
| Kato, T | 1 |
| Kawasaki, M | 1 |
| Takemura, G | 1 |
| Fujiwara, H | 1 |
| Zanetti-Elshater, F | 1 |
| Pingitore, R | 1 |
| Beretta-Piccoli, C | 1 |
| Riesen, W | 1 |
| Heinen, G | 1 |
| Pahor, M | 1 |
| Psaty, BM | 1 |
| Furberg, CD | 1 |
| Sowers, JR | 1 |
| Parving, HH | 1 |
| Fink, KS | 1 |
| Ellsworth, A | 1 |
| Lamarre-Cliche, M | 1 |
| Lambert, R | 1 |
| Van Nguyen, P | 1 |
| Cusson, J | 1 |
| Wistaff, R | 1 |
| Larochelle, P | 1 |
| Gu, Y | 1 |
| Chen, J | 1 |
| Yang, H | 1 |
| Zhu, W | 1 |
| Lin, F | 1 |
| Zhu, C | 1 |
| Lin, S | 1 |
| Studney, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 6-Week Multi-center, Randomized, Double-Blind, Parallel Group Study Comparing the Efficacy of Amlodipine Besylate/Benazepril Versus Amlodipine in the Treatment of Severe Hypertension[NCT00136851] | Phase 4 | 259 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| The Novel Antihypertensive Goal Of hYpertension With diAbetes - Hypertensive Events and ARb Treatment (NAGOYA-HEART) Study[NCT00129233] | Phase 4 | 1,150 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension[NCT00170950] | Phase 3 | 11,506 participants (Actual) | Interventional | 2003-10-31 | Terminated (stopped due to The study was terminated early because of significant efficacy results for the primary endpoint in favor of benazepril/amlodipine treatment.) | ||
| Medication Adherence Given Individual SystemCHANGE(TM) in Advancing Nephropathy (MAGICIAN) Pilot Study[NCT04616612] | 150 participants (Anticipated) | Interventional | 2021-12-15 | Recruiting | |||
| A Cluster Randomized Trial On Cardiovascular Risk Factor Management: Caduet Versus Usual Care In Subjects With Hypertension And Additional Cardiovascular Risk Factors In Clinical Practice[NCT00407537] | Phase 4 | 1,531 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| A Randomized, Double-Blind, Parallel Group Study Evaluating the Efficacy and Safety of Co-Administration of a Triple Combination Therapy of Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide in Subjects With Hypertension[NCT00649389] | Phase 3 | 2,500 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
CV mortality was defined as death due to sudden cardiac death, fatal MI, fatal stroke, coronary intervention, congestive heart failure (CHF), or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV mortality event, MI (non-fatal), or stroke (non-fatal) (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])
| Intervention | Percentage of Patients with an Event (Number) |
|---|---|
| Benazepril/Amlodipine | 5.0 |
| Benazepril/Hydrochlorothiazide | 6.3 |
Cardiovascular morbidity was defined as including any of the following events: non-fatal MI, non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure (PCI or CABG). (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])]
| Intervention | Percentage of Patients with an Event (Number) |
|---|---|
| Benazepril/Amlodipine | 8.6 |
| Benazepril/Hydrochlorothiazide | 10.3 |
CV morbidity was defined as non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure. CV mortality was defined as death due to MI, stroke, coronary intervention, congestive heart failure (CHF), sudden cardiac death, or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity or mortality event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])
| Intervention | Percentage of Patients with an event (Number) |
|---|---|
| Benazepril/Amlodipine | 9.6 |
| Benazepril/Hydrochlorothiazide | 11.8 |
(NCT00407537)
Timeframe: Baseline, Month 12
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Caduet | -10.0128 |
| Usual Care | -6.8429 |
(NCT00407537)
Timeframe: Baseline, Month 4
| Intervention | mmHG (Least Squares Mean) |
|---|---|
| Caduet | -8.3024 |
| Usual Care | -6.6908 |
(NCT00407537)
Timeframe: Baseline, Month 12
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Caduet | -18.2409 |
| Usual Care | -12.4903 |
(NCT00407537)
Timeframe: Baseline, Month 4
| Intervention | mmHG (Least Squares Mean) |
|---|---|
| Caduet | -15.3088 |
| Usual Care | -12.1619 |
European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. The coefficients were used to derive the score calculated after 4 months of study treatment (Month 4). (NCT00407537)
Timeframe: Baseline, Month 4
| Intervention | percent risk (Mean) |
|---|---|
| Caduet | 3.1 |
| Usual Care | 3.7 |
European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. The coefficients were used to derive the score calculated after 12 months of study treatment (Month 12). (NCT00407537)
Timeframe: Baseline, Month 12
| Intervention | percent risk (Mean) |
|---|---|
| Caduet | 3.0 |
| Usual Care | 3.7 |
"Stroke risk calculated from the Framingham risk for CVD (CHD, stroke, intermittent claudication, congestive heart failure) multiplied by a gender-specific calibration factor for the stroke component risk. Coefficients were used to derive the score calculated at the end of study treatment (Month 12)." (NCT00407537)
Timeframe: Baseline, Month 12
| Intervention | percent risk (Mean) |
|---|---|
| Caduet | 3.7 |
| Usual Care | 4.9 |
"Stroke risk calculated from the Framingham risk for CVD (CHD, stroke, intermittent claudication, congestive heart failure) multiplied by a gender-specific calibration factor for the stroke component risk. Coefficients were used to derive the score calculated at the end of study treatment (Month 12)." (NCT00407537)
Timeframe: Baseline, Month 4
| Intervention | percent risk (Mean) |
|---|---|
| Caduet | 3.7 |
| Usual Care | 4.9 |
Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. The coefficients were used to derive the score calculated after 4 months of treatment (Month 4). (NCT00407537)
Timeframe: Baseline, Month 4
| Intervention | percent risk (Mean) |
|---|---|
| Caduet | 12.5 |
| Usual Care | 16.3 |
Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. The coefficients were used to derive the score calculated at the end of study treatment (Month 12). (NCT00407537)
Timeframe: Baseline, Month 12
| Intervention | percent risk (Mean) |
|---|---|
| Caduet | 12.5 |
| Usual Care | 16.3 |
European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. Change from baseline calculated as mean at observation minus mean at Baseline. (NCT00407537)
Timeframe: Baseline, Month 4, Month 12
| Intervention | percent risk (Least Squares Mean) | |
|---|---|---|
| Month 4 | Month 12 | |
| Caduet | -1.8438 | -1.9693 |
| Usual Care | -0.9678 | -0.9963 |
Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. Change from baseline calculated as mean at observation minus mean at Baseline. (NCT00407537)
Timeframe: Baseline, Month 4, Month 12
| Intervention | percent risk (Least Squares Mean) | |
|---|---|---|
| Month 4 | Month 12 | |
| Caduet | -7.2705 | -7.2374 |
| Usual Care | -2.5155 | -2.5167 |
Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations. (NCT00407537)
Timeframe: Baseline, Month 12
| Intervention | mg/dL (Least Squares Mean) | |||
|---|---|---|---|---|
| TC | LDL | HDL | Triglycerides | |
| Caduet | -37.1024 | -33.2420 | -0.4339 | -15.2270 |
| Usual Care | -4.0368 | -3.4168 | -1.0105 | 3.0398 |
Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations. Change from baseline measured as mean at Month 4 minus mean at Baseline. (NCT00407537)
Timeframe: Baseline, Month 4
| Intervention | mg/dL (Least Squares Mean) | |||
|---|---|---|---|---|
| TC | LDL | HDL | Triglycerides | |
| Caduet | -42.7542 | -38.2765 | -0.2060 | -20.5645 |
| Usual Care | -3.8144 | -2.9628 | -1.1978 | 3.0828 |
Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations. (NCT00407537)
Timeframe: Month 12
| Intervention | mg/dL (Mean) | |||
|---|---|---|---|---|
| TC | LDL | HDL | Triglycerides | |
| Caduet | 163.3 | 87.1 | 47.3 | 151.5 |
| Usual Care | 196.6 | 117.3 | 47.1 | 166.4 |
Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations. (NCT00407537)
Timeframe: Month 4
| Intervention | mg/dL (Mean) | |||
|---|---|---|---|---|
| TC | LDL | HDL | Triglycerides | |
| Caduet | 156.0 | 80.9 | 47.6 | 143.5 |
| Usual Care | 195.2 | 116.4 | 46.8 | 164.8 |
(NCT00407537)
Timeframe: Month 12
| Intervention | mmHg (Mean) | |
|---|---|---|
| Systolic | Diastolic | |
| Caduet | 130.6 | 79.2 |
| Usual Care | 134.3 | 81.1 |
(NCT00407537)
Timeframe: Month 4
| Intervention | mmHg (Mean) | |
|---|---|---|
| Systolic | Diastolic | |
| Caduet | 133.5 | 80.7 |
| Usual Care | 134.5 | 81.1 |
Treatments indicative of prescribed medications other than study provided Caduet. (NCT00407537)
Timeframe: Month 4
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Increased dose | increased dose of anti-hypertensive medications | increased dose of lipid lowering medications | increase in either medication | increase in both medications | |
| Caduet | 30 | 30 | 0 | 4 | 0 |
| Usual Care | 90 | 88 | 2 | 45 | 0 |
Treatments indicative of prescribed medications other than study provided Caduet. (NCT00407537)
Timeframe: Month 4, Month 12
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Month 4: anti-hypertensive and/or lipid lowering | Month 4: anti-hypertensive | Month 4: lipid lowering | Month 4: anti-hypertensive and lipid lowering | Month 12: anti-hypertensive and/or lipid lowering | Month 12: anti-hypertensive | Month 12: lipid lowering | Month 12: anti-hypertensive and lipid lowering | |
| Caduet | 648 | 647 | 45 | 44 | 655 | 654 | 46 | 45 |
| Usual Care | 642 | 637 | 202 | 197 | 642 | 638 | 208 | 204 |
Goals set at <140/90 mmHg according to the seventh Joint National Committee (JNC) on prevention, detection, evaluation, and treatment of high blood pressure and <140/90 mm Hg or <130/80 mm Hg for diabetics ccording to the European Society of Cardiology (ESC) guidelines. (NCT00407537)
Timeframe: Month 4, Month 12
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| JNC Month 4 | JNC Month 12 | ESC Month 4 | ESC Month 12 | |
| Caduet | 65.2 | 76.1 | 48.6 | 58.2 |
| Usual Care | 62.6 | 60.6 | 46.0 | 47.5 |
Goal set at <100 mg/dL according to the United States (US) National Cholesterol Education Program Adult Treatment Panel 3 and at <80 mg/dL according to the European (EU) Society of Cardiology guidelines. (NCT00407537)
Timeframe: Month 4, Month 12
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| US Month 4 | US Month 12 | EU Month 4 | EU Month 12 | |
| Caduet | 77.3 | 71.9 | 52.4 | 46.7 |
| Usual Care | 28.2 | 28.8 | 13.3 | 11.5 |
(NCT00649389)
Timeframe: baseline to 12 weeks
| Intervention | mm Hg (Mean) |
|---|---|
| OM40/AML10 | -17.8 |
| OM40/HCTZ25 | -16.5 |
| AML10/HCTZ25 | -14.8 |
| OM40/AML10/HCTZ25 | -21.5 |
(NCT00649389)
Timeframe: Baseline to week 12
| Intervention | mm Hg (Mean) |
|---|---|
| OM40/AML10 | -31.1 |
| OM40/HCTZ25 | -31.2 |
| AML10/HCTZ25 | -28.9 |
| OM40/AML10/HCTZ25 | -38.1 |
(NCT00649389)
Timeframe: Baseline to 12 weeks
| Intervention | Percentage of subjects (Number) |
|---|---|
| OM40/AML10 | 46.0 |
| OM40/HCTZ25 | 46.6 |
| AML10/HCTZ25 | 34.9 |
| OM40/AML10/HCTZ25 | 64.3 |
(NCT00649389)
Timeframe: Baseline to 12 weeks or early termination
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Diastolic blood pressure | Systolic blood pressure | |
| AML10/HCTZ25 | -10.7 | -18.5 |
| OM40/AML10 | -13.9 | -23.5 |
| OM40/AML10/HCTZ25 | -18.0 | -30.3 |
| OM40/HCTZ25 | -14.5 | -23.9 |
11 reviews available for amlodipine and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Blood Pressure Variability in Patients with Diabetes Mellitus with Hypertension: Treatment Recommendations and Role of Amlodipine.
Topics: Amlodipine; Blood Pressure; Calcium Channel Blockers; Diabetes Complications; Diabetes Mellitus; Hum | 2017 |
Amlodipine in the Era of New Generation Calcium Channel Blockers.
Topics: Albuminuria; Amlodipine; Atherosclerosis; Calcium Channel Blockers; Diabetes Complications; Diabetic | 2018 |
Blood pressure response with fixed-dose combination therapy: comparing hydrochlorothiazide with amlodipine through individual-level meta-analysis.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Blood P | 2013 |
Meta-analysis of three observational studies of amlodipine/valsartan in hypertensive patients with additional risk factors.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Diabetes Complication | 2013 |
Effectiveness of the fixed-dose combination of olmesartan/amlodipine/hydrochlorothiazide for the treatment of hypertension in patients stratified by age, race and diabetes, CKD and chronic CVD.
Topics: Age Factors; Amlodipine; Cardiovascular Diseases; Diabetes Complications; Drug Therapy, Combination; | 2013 |
Telmisartan plus amlodipine single-pill combination for the management of hypertensive patients with a metabolic risk profile (added-risk patients).
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzo | 2013 |
Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence.
Topics: Amlodipine; Calcium Channel Blockers; Coronary Disease; Diabetes Complications; Diabetes Mellitus; E | 2002 |
Effect of amlodipine on systolic blood pressure.
Topics: Age Factors; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Complications; Dose-Respo | 2003 |
The Anglo-Scandinavian Cardiac Outcomes Trial-- blood pressure lowering arm.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blockers | 2006 |
Calcium antagonists and cardiovascular risk in diabetes.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 1998 |
Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.
Topics: Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2002 |
11 trials available for amlodipine and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Predictors of cardiac morbidity in diabetic, new-onset diabetic and non-diabetic high-risk hypertensive patients: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Complications; Female; Heart Failure; | 2016 |
Comparative efficacy and safety of amlodipine/benazepril combination therapy and amlodipine monotherapy in severe hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Benzazepines; Chron | 2010 |
Rationale and design of the NAGOYA HEART Study: comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium C | 2010 |
Cardiovascular events during differing hypertension therapies in patients with diabetes.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; B | 2010 |
Management of home blood pressure by amlodipine combined with angiotensin II receptor blocker in type 2 diabetes.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Diabete | 2012 |
Proactive cardiovascular risk management versus usual care in patients with and without diabetes mellitus: CRUCIAL trial subanalysis.
Topics: Adult; Aged; Amlodipine; Blood Pressure; Diabetes Complications; Diabetes Mellitus; Drug Combination | 2012 |
Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Complications; Double-B | 2012 |
Amlodipine added to quinapril vs quinapril alone for the treatment of hypertension in diabetes: the Amlodipine in Diabetes (ANDI) trial.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure Determination; Calcium Channel Blockers; Diabete | 2007 |
Calcium antagonists for treatment of diabetes-associated hypertension. Metabolic and renal effects of amlodipine.
Topics: Adult; Aged; Albuminuria; Amlodipine; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Diabe | 1994 |
Comorbidity of hypertension and diabetes: the fosinopril versus amlodipine cardiovascular events trial (FACET)
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 1998 |
[Calcium channel blocking agents and albuminuria in diabetic and hypertensive patients. A pilot study].
Topics: Absorption; Aged; Albuminuria; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Creati | 2000 |
11 other studies available for amlodipine and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Comparison of amlodipine versus other calcium channel blockers on blood pressure variability in hypertensive patients in China: a retrospective propensity score-matched analysis.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; China; Cohort S | 2018 |
Evaluation of safety and efficacy of telmisartan-amlodipine combination in treating hypertension.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antih | 2008 |
Assessment on antihypertensive effect and safety of nifedipine controlled-release tablet administered at 80 mg/day in practical clinic.
Topics: Adult; Age Factors; Aged; Ambulatory Care Facilities; Amlodipine; Antihypertensive Agents; Blood Pre | 2012 |
Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Creatinine; Di | 2012 |
Changing characteristics of patients with vasospastic angina in the era of new calcium channel blockers.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Amlodipine; Angina Pectoris, Variant; Ca | 2004 |
Adult hypertension: reducing cardiovascular morbidity and mortality.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Alcohol Drinking | 2005 |
Effects of benidipine and some other calcium channel blockers on the prognosis of patients with vasospastic angina. Cohort study with evaluation of the ergonovine coronary spasm induction test.
Topics: Adult; Aged; Aging; Amlodipine; Angina Pectoris; Calcium Channel Blockers; Cohort Studies; Coronary | 2007 |
Treatment of hypertensive patients with diabetes.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 1998 |
Antihypertensive treatment and CHD in the elderly.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; | 1999 |
[Diabetic patient with hypertension takes A-I I blocker. Less likely dialysis].
Topics: Albuminuria; Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2002 |
[The effects of endothelin blockade on renal expression of angiotensin II type 1 receptor in diabetic hypertensive rats].
Topics: Amlodipine; Animals; Antihypertensive Agents; Bosentan; Cilazapril; Diabetes Complications; Diabetes | 2002 |